
    
      This is the open-label extension to the randomized, double-blind, placebo- and
      ropinirole-controlled SP513 trial that assessed the efficacy and safety and tolerability of
      the Rotigotine patch in subjects with early-stage idiopathic Parkinson's Disease
    
  